Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

This study has been completed.
Sponsor:
Information provided by:
Baxter Healthcare Corporation
ClinicalTrials.gov Identifier:
NCT00782106
First received: October 29, 2008
Last updated: October 28, 2010
Last verified: October 2010

October 29, 2008
October 28, 2010
December 2006
November 2007   (final data collection date for primary outcome measure)
Ability to administer, after priming with recombinant human hyaluronidase, at least one half of a 4-week dose (minimum of 200 mg/kg) of IgG in a single infusion site, via the subcutaneous route, with no more than mild local adverse drug reactions. [ Time Frame: 72 hours ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00782106 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)

The purpose of the study is to determine the feasibility of infusing a full 4-week dose of Immune Globulin Intravenous (Human), 10% in a single subcutaneous site and the amount of recombinant human hyaluronidase needed to infuse that dose with no more than mild local adverse drug reactions.

Not Provided
Interventional
Phase 1
Phase 2
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Primary Immune Deficiency
  • Biological: Recombinant human hyaluronidase + immune globulin intravenous
    Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
    Other Names:
    • rHuPH20 = Recombinant Human Hyaluronidase
    • IGIV, 10% = Immune Globulin Intraveneous (Human), 10%
  • Biological: Recombinant human hyaluronidase + immune globulin intravenous
    1. IV infusion of IGIV, 10% to determine pharmacokinetics
    2. Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
    Other Names:
    • rHuPH20 = Recombinant Human Hyaluronidase
    • IGIV, 10% = Immune Globulin Intraveneous (Human), 10%
  • Experimental: 1
    Tolerability of subcutaneous infusions
    Intervention: Biological: Recombinant human hyaluronidase + immune globulin intravenous
  • Experimental: 2
    Tolerability of subcutaneous infusions and pharmacokinetics
    Intervention: Biological: Recombinant human hyaluronidase + immune globulin intravenous
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
11
November 2007
November 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written informed consent from either the subject or the subject's legally acceptable representative
  • Diagnosis of a PID disorder as defined by World Health Organization criteria1 for which the subject had been receiving a regimen of weekly or biweekly (every-other-week) subcutaneous IgG infusions or IGIV infusions every 21 to 28 days over a period of at least 8 weeks pre-study at an equivalent of a 4-week dose of 300 to 800 mg/kg bodyweight
  • Adults/adolescents aged 16 years and older)
  • For female subjects of child-bearing age: negative urine pregnancy test result at study entry and agreement to employ adequate birth control measures for the duration of the study

Exclusion Criteria:

  • Subjects positive at enrollment for one or more of the following: HBsAg, PCR for HCV, PCR for HIV Type 1
  • Subjects with levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal for the testing laboratory
  • Subjects with neutropenia (defined as an absolute neutrophil count [ANC] <= 500/mm3).
  • Subjects with serum creatinine levels greater than 1.5 times the upper limit of normal for age and gender
  • Subjects with current history of malignancy
  • Subjects with a history of thrombotic episodes (deep vein thrombosis, myocardial infarction, cerebrovascular accident)
  • Subjects with abnormal protein loss (protein losing enteropathy, nephritic syndrome, severe lung disease)
  • Subjects with anemia that in the opinion of the investigator precluded phlebotomy for laboratory studies
  • Subjects who had been exposed to any blood or blood product other than an intravenous immunoglobulin (IGIV), SC immunoglobulin (SCIG), immune serum globulin (ISG) preparations, or albumin within the 6 months prior to study entry.
  • Subjects with an ongoing history of hypersensitivity or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IGIV, SCIG and/or ISG infusions
  • Subjects with IgA deficiency and known anti IgA antibodies
  • Subjects who had received antibiotic therapy for the treatment of infection within 7 days prior to enrollment
  • Subjects who had participated in another clinical study involving an investigational product or device within 28 days prior to study entry
  • Subjects with inability or unwillingness to meet all the requirements of this study
  • If female, pregnancy or lactation at time of study entry
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00782106
160602
No
Richard Schiff, MD, PhD; Medical Director, Baxter Healthcare Corporation
Baxter Healthcare Corporation
Not Provided
Not Provided
Baxter Healthcare Corporation
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP